{"id":26423,"date":"2024-10-29T09:51:31","date_gmt":"2024-10-29T08:51:31","guid":{"rendered":"https:\/\/idibell.cat\/?p=26423"},"modified":"2024-10-29T09:58:05","modified_gmt":"2024-10-29T08:58:05","slug":"identifiquen-6-regions-genetiques-que-podrien-reduir-el-risc-cardiovascular","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2024\/10\/identifiquen-6-regions-genetiques-que-podrien-reduir-el-risc-cardiovascular\/","title":{"rendered":"Identifiquen 6 regions gen\u00e8tiques que podrien reduir el risc cardiovascular"},"content":{"rendered":"
Un equip d\u2019investigadors de l\u2019IDIBELL, l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO), l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Girona Dr. Josep Trueta (IDIBGI), l\u2019IRB Barcelona i l\u2019Institut de Recerca Germans Trias i Pujol (IGTP) ha treballat conjuntament per identificar possibles gens associats a certs metab\u00f2lits \u2013 mol\u00e8cules involucrades en processos bioqu\u00edmics del cos \u2013 i al risc cardiovascular. Els cient\u00edfics van analitzar els nivells de 187 d\u2019aquests compostos en mostres de plasma de 4.974 participants de la cohort catalana GCAT. Van integrar la informaci\u00f3 obtinguda amb altres bases de dades gen\u00e8tiques d\u2019individus europeus, fins a un total de 40.000, i les van tornar a analitzar. Com a resultat, es van identificar 44 regions gen\u00e8tiques associades a aquest metab\u00f2lits.<\/p>\n
Per tal d\u2019identificar com aquestes regions gen\u00e8tiques operen sobre els metab\u00f2lits, els resultats es van combinar amb panells d’expressi\u00f3 g\u00e8nica de 58 tipus diferents de teixits i c\u00e8l\u00b7lules. Els investigadors van poder identificar els gens que, a trav\u00e9s de la modulaci\u00f3 de la seva expressi\u00f3, son causants dels nivells d\u2019aquestes mol\u00e8cules a l’organisme. Aquesta mateixa metodologia tamb\u00e9 la van aplicar als resultats de tres estudis europeus que inclo\u00efen uns 700.000 participants, amb l’objectiu d’investigar la relaci\u00f3 entre l’expressi\u00f3 g\u00e8nica i esdeveniments cardiovasculars, com infarts. Finalment, els investigadors van explorar la relaci\u00f3 de causa entre l’expressi\u00f3 g\u00e8nica, els nivells de metab\u00f2lits i el risc cardiovascular amb una an\u00e0lisi gen\u00e8tica de mediaci\u00f3.<\/p>\n
Gr\u00e0cies a les diverses an\u00e0lisis que han dut a terme, els investigadors han acabat identificant el potencial mecanisme molecular pel qual 6 loci<\/em> gen\u00e8tics (regions gen\u00e8tiques) estan associats a risc cardiovascular a trav\u00e9s dels metab\u00f2lits que regulen<\/strong>. Aix\u00ed doncs, el treball publicat a Genome Medicine<\/em> posa al punt de mira noves dianes g\u00e8niques amb potencial terap\u00e8utic, proposa nous objectius per al desenvolupament de f\u00e0rmacs i ajuda a comprendre millor els mecanismes subjacents del risc cardiovascular.<\/p>\n Regular els nivells de metab\u00f2lits en sang mitjan\u00e7ant la modulaci\u00f3 de l’expressi\u00f3 g\u00e8nica podria oferir una nova via per reduir els esdeveniments cardiovasculars en poblacions de risc. En concret, l’article permet identificar l\u00edpids, com els greixos, que actuen com a mediadors entre l’expressi\u00f3 de determinats gens i el risc cardiovascular. Per tant, es descriu una cadena de factors de risc que van des de la predisposici\u00f3 gen\u00e8tica fins al risc cardiovascular, passant per l\u2019activaci\u00f3 dels gens i els nivells de l\u00edpids en sang.<\/p>\n L\u2019estudi subratlla la import\u00e0ncia de la recerca gen\u00e8tica a gran escala per identificar nous biomarcadors i estrat\u00e8gies terap\u00e8utiques. La identificaci\u00f3 de gens clau associats amb els metab\u00f2lits i el risc cardiovascular ofereix l’oportunitat de desenvolupar tractaments personalitzats, millorant la prevenci\u00f3 i el tractament de les malalties cardiovasculars, que segueixen sent una de les principals causes de mortalitat a nivell mundial.<\/p>\n <\/p>\n <\/p>\n L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Investigadors de cinc centres de recerca catalans han col\u00b7laborat en un estudi gen\u00e8tic a gran escala buscant nous biomarcadors i vies terap\u00e8utiques que podrien reduir el risc cardiovascular mitjan\u00e7ant la modulaci\u00f3 de metab\u00f2lits sanguinis.<\/p>\n","protected":false},"author":8,"featured_media":26424,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,375,447],"tags":[],"class_list":["post-26423","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-colorectal","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 08:07:05","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=26423"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26423\/revisions"}],"predecessor-version":[{"id":26425,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/26423\/revisions\/26425"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/26424"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=26423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=26423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=26423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}